AstraZeneca PLCAZN:LSE

4,502.5
35.50 / 0.8%
3.28m
9.3%
0.6662
Close in GBXToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of Jul 01 2016 17:07 BST.

About the company

18.61bn2.20bn199261.50k
Revenue in GBP (TTM)Net income in GBPIncorporatedEmployees
IndustryPharmaceuticals & BiotechnologyLocation
AstraZeneca PLC
- Legal Department, 2 Kingdom Street
LONDONW2 6BD
United Kingdom
GBR
Phone+44 20 7304 5000Fax+44 20 7604 8151Websitehttp://www.astrazeneca.com/
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Company has its operations in over 100 countries. The Company's pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development. The Company is developing a Toll-like receptor 9 (TLR-9) receptor agonist aimed at producing long-term benefit in asthma by addressing imbalances in the immune system. AstraZeneca offers various products, including Accolate, Rhinocort, Bricanyl Turbuhaler, Rhinocort, Symbicort pMDI, Crestor, Seloken/Toprol-XL, Brilinta/Brilique (ticagrelor), Bydureon, Xigduo XR, Kombiglyze XR and metformin XR, among others.

Mergers & acquisitions

Acquired company
Deal status
DateAZN:LSE since
announced
Transaction
value
Takeda Pharmaceutical Co Ltd-Respiratory BusinessDeal completed16 Dec 2015+2.5 %575.00m
Acerta Pharma BVDeal completed14 Dec 2015+4.0 %4.00bn
ZS Pharma IncDeal completed06 Nov 2015+6.0 %2.69bn
Amgen Inc-Biologics Bulk Manufacturing FacilityDeal completed11 Sep 2015+4.9 %--
Data delayed at least 15 minutes, as of Jul 01 2016 17:07 BST.

Peer analysis

Company Revenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings
(TTM)
Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excluding
extraordinary items (TTM)
EPS (including
extraordinary items) (TTM)
Revenue per
share (TTM)
Book value per
share (MRQ)
Asset turnover
(TTM)
Inventory turnover
(TTM)
Receivables turnover
(TTM)
Revenues per
employee (TTM)
Return on
average
assets
(TTM)
Return on
average
assets
(5 yr average)
Return on
investment
(TTM)
Return on
investment
(5 yr average)
Gross margin (TTM)Gross margin (5 yr average)Net profit margin (TTM)Net Profit margin (5 Yr Average)Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio (5 yr average)Revenue
(Year-over-year change%)
Revenue
(5 yr growth rate)
Net income
(Year-over-year change%)
Net income
(5 Yr growth rate)
Capital
expenditure
(5 Yr growth rate)
Dividend
(5 yr growth rate)
Actelion Ltd
1.64bn441.42m14.40bn2.50k31.6311.9728.508.795.165.1619.0713.640.89982.364.78--24.0512.8630.8917.0291.4689.3326.7318.802.3236.990.0036.584.451.18-7.06257.16-20.366113.40
Shire PLC
4.99bn1.00bn42.07bn5.55k27.703.6427.708.431.691.668.4112.870.31811.565.47899,1396.4016.518.2121.9285.0985.5020.1229.440.395322.580.40017.776.5513.08-59.257317.86-19.016915.17
AstraZeneca plc
18.61bn2.20bn56.99bn61.50k25.975.1414.323.061.741.7414.718.760.41971.973.94302,6454.918.196.8711.4582.8180.7011.7116.480.65435.110.49578.91-6.9273-5.7764129.12-18.90165.031.89
GlaxoSmithKline plc
24.53bn615.00m78.17bn101.19k127.9927.8328.353.190.12540.12545.040.57660.43621.704.32242,4111.2212.631.8319.4066.4369.952.8021.150.76816.790.721975.343.99-3.3673205.5938.813.064.24
Sanofi SA
28.99bn3.72bn80.86bn115.63k22.18--14.802.793.383.3126.37--------298,960--4.56--5.3068.7668.4012.8213.16--28.64--78.898.940.48023.23-4.201810.773.23
Novo Nordisk A/S
12.39bn3.88bn81.23bn41.57k26.6624.9519.296.5613.4313.4342.8814.351.381.317.062,705,32543.1035.2989.7355.7484.9583.2431.3329.450.81289.690.010846.7521.5312.1731.6419.3410.4526.19
Data as of Jul 01 2016. Currency figures normalised to AstraZeneca PLC's reporting currency: .
Data delayed at least 20 minutes, as of Jul 01 2016 22:03 BST.

Institutional shareholders

HolderShares% Held
BlackRock Investment Management (UK) Ltd.
as of 31 Jan 2016
53.17m4.2%
Wellington Management Co. LLP
as of 01 May 2016
38.44m3.0%
Legal & General Investment Management Ltd.
as of 01 May 2016
36.68m2.9%
The Vanguard Group, Inc.
as of 01 May 2016
30.17m2.4%
BlackRock Advisors LLC
as of 01 May 2016
23.78m1.9%
Invesco Asset Management Ltd.
as of 01 May 2016
23.12m1.8%
Woodford Investment Management LLP
as of 01 May 2016
22.23m1.8%
Norges Bank Investment Management
as of 01 May 2016
21.56m1.7%
Threadneedle Asset Management Ltd.
as of 01 May 2016
19.40m1.5%
State Street Global Advisors Ltd.
as of 01 May 2016
17.72m1.4%
22.6%
Per cent of shares
held by top holders
Data from 31 Dec 2015 - 23 Jun 2016Source: FactSet Research Systems Inc.
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.